A Study of LX107 Gene Therapy in AIPL1-IRD Patients

NCT07063030 | Recruiting Early Phase 1

• 1 other identifier: SHGH-LX107
• Study Type: interventional
• Target: 13
• Locations: 1 country
• Sites: 1

Brief Summary

Administering subretinal injection of LX107 injection (a gene therapy drug) to patients with retinal dystrophy caused by AIPL1 gene mutation to evaluate its efficacy and safety.

Conditions

Retinal Dystrophy

Outcome Measures

Primary Outcomes (1)

• Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

  Incidence of ocular and non-ocular adverse events (AEs) and serious adverse events (SAEs) following LX107 subretinal injection

  6 Months

Secondary Outcomes (5)

• Changes in Functional Magnetic Resonance Imaging (fMRI) Results

  6 months、12 months

• Mean Change from Baseline in Multi-luminance Mobility Test (MLMT)

  6 months、12 months

• Mean Change from Baseline in Full-Field Sensitivity Threshold (FST)

  6 months、12 months

• Mean Change from Baseline in Visual Acuity (VA)

  6 months、12 months

• Mean Change from Baseline in Visual Fields

  6 months、12 months

Study Arms (1)

Intervention

EXPERIMENTAL

Experimental: LX107 Injection Arm Description: * Low dose group: subretinal injection of LX107 -3×10⁹ VG/eye * Medium dose group: subretinal injection of LX107- 1×10¹⁰ VG/eye * High dose group: subretinal injection of LX107 -3×10¹⁰ VG/eye

Genetic: LX107 Injection

Interventions

LX107 Injection GENETIC

Subjects will receive subretinal injection of LX107 on Day 0.

Intervention

Eligibility Criteria

• Age: 4 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• The subject and/or their guardian signs a written informed consent form and is willing to comply with the long-term follow-up protocol and supporting protocols.
• Adult or pediatric patients (aged ≥ 4 years) diagnosed with AIPL1-IRD.
• Definitive molecular diagnosis of biallelic AIPL1 gene mutations confirmed by next-generation sequencing combined with Sanger validation.
• The study eye has a best-corrected visual acuity of no more than 58 letters (approximately equivalent to decimal visual acuity ≤ 0.3) using the ETDRS visual acuity chart at baseline.
• Note: Only one eye will be designated as the "study eye" (i.e., the eye to receive treatment) at the investigator's discretion.

You may not qualify if:

• A history of ocular diseases that, in the investigator's judgment, may hinder the planned treatment or interfere with the interpretation of study endpoints (e.g., glaucoma, diabetic retinopathy, retinal vein occlusion, retinal detachment, posterior or panuveitis, etc.).
• Any eye with a history of gene therapy for IRD or other hereditary neuro-ophthalmic diseases (including but not limited to other viral vector-based gene therapies, mRNA therapies, etc.).
• A lack of sufficient viable retinal cells as determined by non-invasive methods such as OCT or ophthalmoscopy.
• Any active intraocular or periocular infection in the study eye (e.g., infectious conjunctivitis, keratitis, scleritis, endophthalmitis, infectious blepharitis, uveitis).
• A history of intraocular surgery (e.g., vitrectomy, cataract surgery, trabeculectomy, or other filtering surgery) in the 6 months prior to the screening visit.
• For any systemic conditions:
• Uncontrolled hypertension, defined as systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg. If the initial measurement exceeds the above limits, it may be repeated on the same day or another day during the screening period; if the subject is taking oral antihypertensive drugs, they must have been on a stable dose of the same drug for at least 30 days prior to screening.
• Diabetic patients meeting any of the following criteria: ① known to have macrovascular complications; ② baseline HbA1c \> 7.5%; ③ receiving treatment with two or more oral hypoglycemic agents, insulin, or GLP-1 receptor agonists.
• A history of any other diseases, metabolic disorders, physical examination findings, or clinical laboratory abnormalities that, in the investigator's judgment, may contraindicate the use of the study drug, interfere with the interpretation of study results, or place the subject at high risk of treatment complications, including but not limited to: AIDS, syphilis, acute/chronic active hepatitis B or C, coagulation disorders, a history of treated or untreated malignancy within the past 5 years (except for localized basal cell carcinoma of the skin or in situ cervical cancer), etc.
• Any of the following laboratory abnormalities: ① platelet count \< 100 × 10⁹/L, hemoglobin (Hb) \< 10 g/dL (males) or \< 9 g/dL (females); ② aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3 × ULN; ③ serum creatinine or urea \> 1.5 × ULN.
• Administration of any other investigational drug (except vitamins and minerals) within 3 months prior to screening, or an attempt to participate in another clinical trial during the study period.
• Other circumstances deemed unsuitable for enrollment by the investigator.
• Unwillingness to use effective contraceptive methods during the study; pregnant or lactating women, or women planning to become pregnant or lactate during the study period.

Sponsors & Collaborators

• Innostellar Biotherapeutics Co.,Ltd: collaborator
• Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine: lead

Study Sites (1)

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, China

RECRUITING

MeSH Terms

Conditions

Retinal Dystrophies

Condition Hierarchy (Ancestors)

Retinal Degeneration; Retinal Diseases; Eye Diseases

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director

Study Record Dates

• First Submitted: July 3, 2025
• First Posted: July 14, 2025
• Study Start: July 15, 2025
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2030
• Last Updated: March 10, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)